| Clinical data | |
|---|---|
| Routes of administration | IV |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C107H179N35O36S7 |
| Molar mass | 2756.24 g·mol |
Leconotide (INN; development codes CNSB004 and AM336; also known as ω-conotoxin CVID) is an ω-conotoxin peptide isolated from the venom of Conus catus which is under investigation as an analgesic drug for the treatment of pain conditions.
It acts as an N-type voltage-gated calcium channel (Cav2.2) blocker and is highly selective for this channel over the related P/Q-type voltage-gated calcium channel (Cav2.1).
Relative to ziconotide, leconotide is advantageous in that it is significantly less toxic, and for that reason can be administered intravenously as opposed to via intrathecal injection.
See also
- Ziconotide, an analgesic peptide derived from the toxin of the cone snail species Conus magus
- Lacosamide, an approved small molecule analgesic and anti-epileptic
- Ralfinamide, an investigational small molecule analgesic
References
- ^ Allerton C, Fox D (2013). Pain Therapeutics: Current and Future Treatment Paradigms. Royal Society of Chemistry. pp. 225–. ISBN 978-1-84973-645-9.
- ^ Stephens G, Mochida S (23 April 2013). Modulation of Presynaptic Calcium Channels. Springer Science & Business Media. pp. 326–. ISBN 978-94-007-6334-0.
- Nervous System Diseases: Advances in Research and Treatment: 2011 Edition. ScholarlyEditions. 9 January 2012. pp. 217–. ISBN 978-1-4649-2221-3.
- Kolosov A, Goodchild CS, Cooke I (February 2010). "CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain". Pain Medicine. 11 (2): 262–73. doi:10.1111/j.1526-4637.2009.00741.x. PMID 20002322.
- Kolosov A, Aurini L, Williams ED, Cooke I, Goodchild CS (June 2011). "Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain". Pain Medicine. 12 (6): 923–41. doi:10.1111/j.1526-4637.2011.01118.x. PMID 21539704.
| Neuropathic pain and fibromyalgia pharmacotherapies | |
|---|---|
| Monoaminergics |
|
| Ion channel blockers |
|
| Others |
|
| Ion channel modulators | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calcium |
| ||||||||||||||||||||||||
| Potassium |
| ||||||||||||||||||||||||
| Sodium |
| ||||||||||||||||||||||||
| Chloride |
| ||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||
| See also: Receptor/signaling modulators • Transient receptor potential channel modulators | |||||||||||||||||||||||||
 | This analgesic-related article is a stub. You can help Misplaced Pages by expanding it. |